Beam Therapeutics Inc. (BEAM)
Beam Therapeutics is a biotech firm using 'base editing' technology to rewrite DNA and potentially cure genetic diseases at their source.
Is Beam Therapeutics Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Pioneering 'base editing' technology with high potential. Worth weighing: Currently losing money on every pound of revenue.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does Beam Therapeutics Inc. do?
Think of Beam as a genetic word processor; instead of just cutting DNA like older methods, they aim to precisely edit individual letters in the genetic code to fix errors. They make money through research partnerships with big pharmaceutical companies, though they are currently spending far more on research than they bring in from these deals. Everything rides on whether their clinical trials can show this complex technology is safe and effective in humans.
On our factor screen it looks strongest on value and momentum, and weakest on growth.
- !Pays no dividend - the whole return rides on the share price
- !Revenue slipped about 94% over the year
- ✓Low debt - a sturdier balance sheet
- —
- Quality screens low
- Growth screens low
- Income screens low
Does Beam Therapeutics Inc. pay a dividend?
No - Beam Therapeutics Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does Beam Therapeutics Inc. have more cash or more debt?
It holds about $1.15B in cash against about $247.36M of debt - so it has net cash of about $905.57M. More cash than debt is a cushion: it does not need to borrow just to cover what it owes.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do Beam Therapeutics Inc.'s numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Beam Therapeutics Inc. actually fallen?
Over the last 2 years of daily prices, Beam Therapeutics Inc. fell as much as −57% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does Beam Therapeutics Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
When does Beam Therapeutics Inc. report earnings, and how did recent quarters go?
Beam Therapeutics Inc. is next scheduled to report on about 2026-11-03 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-08-04 | $-1.13 | $-1.18 | Missed -5% |
| 2026-05-07 | $-1.01 | $-0.91 | Beat +10% |
| 2026-02-24 | $-1.12 | $2.33 | Beat +309% |
| 2025-11-04 | $-1.01 | $-1.10 | Missed -9% |
| 2025-08-05 | $-1.09 | $-1.00 | Beat +8% |
| 2025-05-06 | $-1.17 | $-1.24 | Missed -6% |
Across the last 6 quarters here, Beam Therapeutics Inc. came in ahead of what analysts expected 3 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for Beam Therapeutics Inc.?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
The technology becomes a standard platform for treating multiple genetic diseases.
The technology proves too difficult or expensive to scale for patients.
What are the pros and cons of Beam Therapeutics Inc.?
A balance check, not a score or verdict.
- Pioneering 'base editing' technology with high potential
- Strong revenue growth: How fast the company's sales grew versus a year ago. from strategic partnerships
- Significant intellectual property portfolio
- Currently losing money on every pound of revenue
- High reliance on external funding to keep research going
- Very high share price volatility
- Clinical trials may fail to meet safety or effectiveness standards
- Regulatory bodies could block or delay new treatments
- Rapidly evolving competition in the gene-editing space
The write-up's own warning lights — if these start happening, the case above changes.
- A permanent halt to clinical trials due to safety issues
- The company running out of cash without a new funding source
Common questions about Beam Therapeutics Inc.
Does Beam Therapeutics Inc. pay a dividend?
No - Beam Therapeutics Inc. does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does Beam Therapeutics Inc. report earnings next?
Beam Therapeutics Inc. is next scheduled to report results on about 2026-11-03. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
Tempus AI, Inc.
CRISPR Therapeutics AG
Intuitive Surgical, Inc.
BioNTech SE
Hims & Hers Health, Inc.
Intellia Therapeutics, Inc.
Novavax, Inc.
Smith & NephewBuilt from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.